BioMarin

YTD

ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,221

Employees3,221

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,221

Employees3,221

BMRN Key Statistics

Market cap

13.04B

Market cap13.04B

Price-Earnings ratio

189.38

Price-Earnings ratio189.38

Dividend yield

—

Dividend yield—

Average volume

2.82M

Average volume2.82M

High today

$68.70

High today$68.70

Low today

$67.12

Low today$67.12

Open price

$68.58

Open price$68.58

Volume

1.41M

Volume1.41M

52 Week high

$70.98

52 Week high$70.98

52 Week low

$49.26

52 Week low$49.26

Stock Snapshot

With a market cap of 13.04B, BioMarin(BMRN) trades at $67.36. The stock has a price-to-earnings ratio of 189.38.

On 2026-08-15, BioMarin(BMRN) stock moved within a range of $67.12 to $68.70. With shares now at $67.36, the stock is trading +0.4% above its intraday low and -2.0% below the session's peak.

Trading volume for BioMarin(BMRN) stock has reached 1.41M, versus its average volume of 2.82M.

The stock's 52-week range extends from a low of $49.26 to a high of $70.98.

BMRN News

Simply Wall St 1d

Is BioMarin Pharmaceutical Still Cheap As 2026 Guidance Rises And Amicus Adds Growth?

BioMarin Pharmaceutical (BMRN) updated its full year 2026 guidance after second quarter results that included revenue of US$989.71 million and new contributions...

TipRanks 5d

BioMarin price target raised to $114 from $111 at Canaccord

Canaccord analyst Whitney Ijem raised the firm’s price target on BioMarin (BMRN) to $114 from $111 and keeps a Buy rating on the shares. The firm updated its mo...

Simply Wall St 6d

BioMarin Is Up 6.3% After Raising 2026 Revenue Guidance And Highlighting Voxzogo Momentum

In early August 2026, BioMarin Pharmaceutical reported second-quarter revenue of US$989.71 million, raised its full-year 2026 revenue guidance range, and issued...

Analyst ratings

76%

of 29 ratings

Buy

75.9%

Hold

24.1%

Sell

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.